Leading orphan drugs based on R&D phase III cost 2015
This statistic displays the research and development phase III cost of the top 10 drugs based on net present value, as of 2015. Actelion's Uptravi had a total R&D phase III cost of 185 million U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.